January JPGN Articles
 
1 - Proxy?reported outcome measures (i.e., reports by someone who is not the patient responding as if that person were the patient) are discouraged for use in registration trials as suggested by the FDA PRO Guidance. Which of the following measurement tools uses proxy?reported outcome measures?
A   - Mayo score
B   - Pediatric Ulcerative Colitis Activity Index (PUCAI)
C   - Modified Ulcerative Colitis Activity Index (MUCAI)
D   - All of the above
2 - Only three drugs have been approved by the FDA for the treatment of pediatric ulcerative colitis (UC). Which of the following choices contains all these 3 approved drugs?
A   - Azulfidine, Colazal, and Remicade
B   - Pentasa, Colazal, and Remicade
C   - Pentasa, Imuran, Azanin
D   - Imuran, Azanin, Apriso
3 - Which of the following disease activity indices used in the pediatric UC trials is a FDA preferred measurement for the pediatric UC trials?
A   - Pediatric UC Activity Index (PUCAI)
B   - Simple Clinical Colitis Activity Index (SCCAI)
C   - Sutherland UC Activity Index
D   - None of above
4 - CF patients are potential candidates for probiotic supplementation because:
A   - Probiotics can help treat atopic disease.
B   - Probiotics directly improve their respiratory function.
C   - Probiotics induce pulmonary cell to release TNF-alpha.
D   - The intestinal microflora of CF patients is often abnormal, due to repeated antibiotic use.
5 - What are the mechanisms supporting the use of L.reuteri strains in this study?
A   - The anti-inflammatory intestinal activity of different LR strains has been documented through inhibition of colitis in transgenic IL-10 deficient mice.
B   - Some LR strains exhibit a potent inhibitory effect on TNF-a induced IL-8 expression in human intestinal epithelial cells.
C   - They are able to colonize both upper and lower intestinal mucosa as well as to modulate intestinal immunological response.
D   - All of the answers above.
6 - Which of the following were noted in this study using L.Reuteri ATCC55730 in cystic fibrosis?
A   - Reducing rate of pulmonary exacerbations and upper respiratory infections.
B   - Improvement of the FEV1.
C   - significant changes in TNF-alpha and IL-8 plasmatic concentration.
D   - Decreasing number of gastrointestinal infections.